TELA Bio

1 Great Valley Parkway
Suite 24
Malvern
Pennsylvania
19355
United States

Tel: 484-320-2930

Email: info@telabio.com

Show jobs for this employer

About TELA Bio

TELA Bio, Inc. is a privately-owned company focused on bringing innovative, cost-effective, surgical reconstruction solutions to surgeons, hospitals and patients.

YEAR FOUNDED:

2012

LEADERSHIP:

Founders: Antony Koblish and Maarten Persenaire

Founder and CEO: Antony Koblish

Founder and CMO: Maarten Persenaire

CTO: Skott Greenhalgh

PRODUCTS:

All Products

 

48 articles with TELA Bio

  • TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that the company will report 2020 third quarter financial results on November 11, 2020.

  • TELA Bio, Inc. announced that additional data from its BRAVO study were presented virtually as posters at the Americas Hernia Society Annual Meeting.

  • TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that the company plans to participate in two upcoming conferences.

  • TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported financial results for the second quarter ended June 30, 2020.  Recent Highlights Reported revenue of $3.5 million for the second quarter of 2020, increasing 6% over the second quarter of 2019  

  • TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announces it will be participating in the Canaccord Genuity 40th Annual Growth Conference, scheduled to be held virtually August 11-13, 2020.

  • TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that the company will report 2020 second quarter financial results on August 12, 2020. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial r

  • TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced the results of an interim analysis from the company's post-market BRAVO study evaluating the clinical performance of OviTex for the treatment of ventral hernias.

  • TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the closing of its underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $16.00 per share,

  • TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $16.00 per share for gross proceeds of $48.0 million, before underwriting discounts and commiss

  • TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the commencement of a proposed underwritten public offering of 3,000,000 shares of its common stock.  

  • TELA Bio, Inc. announced that the company will be added to the Russell 2000® Index at the conclusion of the Russell U.S. Indices annual reconstitution, effective after the U.S. market opens on June 26, 2020.

  • TELA Bio, Inc., a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that two abstracts focused on evaluating OviTex® products have been accepted for poster presentations at the 20th annual Minimally Invasive Surgery Symposium.

  • TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the company will be participating in the upcoming Jefferies Virtual Healthcare Conference. TELA Bio's management is scheduled to present on Tuesday, June 2, 2020 at 9:00 AM Eastern Daylight Time (E

  • TELA Bio, Inc., a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, reported financial results for the first quarter ended March 31, 2020.

  • TELA Bio, Inc., a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that the company will report 2020 first quarter financial results on Tuesday, May 12, 2020.

  • TELA Bio, Inc. announced that it has appointed Doug Evans, the President and Chief Executive Officer of Lungpacer Medical Inc., and Lisa Colleran, a principal of LNC Advisors, LLC, to its board of directors effective April 20, 2020.

  • TELA Bio, Inc. ("TELA") today reported financial results for the fourth quarter and full year ended December 31, 2019.  Recent Highlights Recognized revenue of $4.9 million for the fourth quarter and $15.4 million for the full year

  • TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that the company will report 2019 fourth quarter and full year financial results on Friday, March 27, 2020, before market open

  • TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), today announced data from a non-human primate study demonstrating favorable response to reinforced biologic material used in a hernia repair compared to seven clinically used biologic and synthetic products.

  • Pharma and biotech companies strengthen their leadership teams and boards with this week's Movers & Shakers.